Weiyi Zhang
CEO,
RiboX Therapeutics
United States
Dr. Weiyi Zhang is the founding CEO of RiboX Therapeutics, a globally operated biotech founded in 2021 that focuses the effort on developing circular RNA into transformative medicine. Prior to RiboX, Weiyi was Vice President, and Head of External Innovation Hub China at Boehringer Ingelheim. She built and managed innovation functions covering early-stage research collaborations (Research Beyond Borders), Business Development & Licensing in China and Boehringer Ingelheim Venture Fund in Asia. She led the investments and served as board directors of Delonix Bioworks, Nuevocor Therapeutics and RiboX Therapeutics. Prior to Boehringer Ingelheim, Weiyi was working at Innovation Center China at Bayer Healthcare with increasing responsibilities and left Bayer as Associate Director of Innovation Partnering.
Weiyi gained her bachelor’s degree in Biology at Xiamen University in 2001. She joined international Max-Planck research school in chemical biology in 2003 and obtained her Ph.D in cell biology from Ruhr-University Bochum in 2007. Since 2008, Weiyi started postdoc training in functional study of orphan GPCRs in central neural system at both National Institute of Biological Sciences Beijing and the University of Hong Kong.
Suffix
PhD
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}